1. Home
  2. STG vs SKYE Comparison

STG vs SKYE Comparison

Compare STG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunlands Technology Group

STG

Sunlands Technology Group

HOLD

Current Price

$5.92

Market Cap

112.4M

Sector

Real Estate

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.89

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STG
SKYE
Founded
2003
2012
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
44.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STG
SKYE
Price
$5.92
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
4.2K
494.0K
Earning Date
11-20-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.01
N/A
Revenue
$285,589,112.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$0.68
52 Week High
$15.00
$5.75

Technical Indicators

Market Signals
Indicator
STG
SKYE
Relative Strength Index (RSI) 47.67 38.82
Support Level $5.84 $0.68
Resistance Level $6.48 $0.95
Average True Range (ATR) 0.31 0.11
MACD 0.04 -0.00
Stochastic Oscillator 40.95 38.81

Price Performance

Historical Comparison
STG
SKYE

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: